10564685

Source:http://linkedlifedata.com/resource/pubmed/id/10564685

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0026764, umls-concept:C0039736, umls-concept:C0205269, umls-concept:C0441655
pubmed:issue	21
pubmed:dateCreated	1999-11-18
pubmed:abstractText	Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA55819
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/10564685, http://linkedlifedata.com/resource/pubmed/commentcorrection/10564685-10564693, http://linkedlifedata.com/resource/pubmed/commentcorrection/10564685-10744492, http://linkedlifedata.com/resource/pubmed/commentcorrection/10564685-11012329, http://linkedlifedata.com/resource/pubmed/commentcorrection/10564685-11419443
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0255562
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Bence Jones Protein, http://linkedlifedata.com/resource/pubmed/chemical/Myeloma Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Thalidomide
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0028-4793
pubmed:author	pubmed-author:AnaissieEE, pubmed-author:AyersDD, pubmed-author:BarlogieBB, pubmed-author:DesikanRR, pubmed-author:DhodapkarMM, pubmed-author:EddlemonPP, pubmed-author:MehtaJJ, pubmed-author:MunshiNN, pubmed-author:RobersonPP, pubmed-author:SinghalSS, pubmed-author:WilsonCC, pubmed-author:ZeddisJJ
pubmed:issnType	Print
pubmed:day	18
pubmed:volume	341
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1565-71
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:10564685-Angiogenesis Inhibitors, pubmed-meshheading:10564685-Bence Jones Protein, pubmed-meshheading:10564685-Bone Marrow, pubmed-meshheading:10564685-Bone Marrow Examination, pubmed-meshheading:10564685-Disease Progression, pubmed-meshheading:10564685-Drug Administration Schedule, pubmed-meshheading:10564685-Female, pubmed-meshheading:10564685-Humans, pubmed-meshheading:10564685-Male, pubmed-meshheading:10564685-Microcirculation, pubmed-meshheading:10564685-Middle Aged, pubmed-meshheading:10564685-Multiple Myeloma, pubmed-meshheading:10564685-Multivariate Analysis, pubmed-meshheading:10564685-Myeloma Proteins, pubmed-meshheading:10564685-Recurrence, pubmed-meshheading:10564685-Remission Induction, pubmed-meshheading:10564685-Survival Analysis, pubmed-meshheading:10564685-Thalidomide
pubmed:year	1999
pubmed:articleTitle	Antitumor activity of thalidomide in refractory multiple myeloma.
pubmed:affiliation	Myeloma and Lymphoma Program, South Carolina Cancer Center, University of South Carolina, Columbia, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Clinical Trial, Phase II